One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab

Brigitta U. Mueller; Carolyn M. Bennett; Henry A. Feldman; James B. Bussel; Thomas C. Abshire; Theodore B. Moore; Hadi Sawaf; Mignon L. Loh; Zora R. Rogers; Bertil E. Glader; Maggie C. McCarthy; Donald H. Mahoney; Thomas A. Olson; Stephen A. Feig; Adonis N. Lorenzana; William C. Mentzer; George R. Buchanan; Ellis J. Neufeld

doi:10.1002/pbc.21757

One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab

Brigitta U. Mueller, Carolyn M. Bennett, Henry A. Feldman, James B. Bussel, Thomas C. Abshire, Theodore B. Moore, Hadi Sawaf, Mignon L. Loh, Zora R. Rogers, Bertil E. Glader, Maggie C. McCarthy, Donald H. Mahoney, Thomas A. Olson, Stephen A. Feig, Adonis N. Lorenzana, William C. Mentzer, George R. Buchanan, Ellis J. Neufeld

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Background. We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm³ within the first 12 weeks. These patients were followed for the next year. Methods. Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results. Eight of the 11 initial responders maintained a platelet count over 150,000/mm³ without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm³ without the need for further intervention. Conclusions. Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm ³ or higher in 11 of 36 patients (31%).

Original language	English (US)
Pages (from-to)	259-262
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	52
Issue number	2
DOIs	https://doi.org/10.1002/pbc.21757
State	Published - Feb 2009

Keywords

Clinical trial
Immune thrombocytopenia
Rituximab

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.21757

Cite this

Mueller, B. U., Bennett, C. M., Feldman, H. A., Bussel, J. B., Abshire, T. C., Moore, T. B., Sawaf, H., Loh, M. L., Rogers, Z. R., Glader, B. E., McCarthy, M. C., Mahoney, D. H., Olson, T. A., Feig, S. A., Lorenzana, A. N., Mentzer, W. C., Buchanan, G. R., & Neufeld, E. J. (2009). One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab. Pediatric Blood and Cancer, 52(2), 259-262. https://doi.org/10.1002/pbc.21757

Mueller, BU, Bennett, CM, Feldman, HA, Bussel, JB, Abshire, TC, Moore, TB, Sawaf, H, Loh, ML, Rogers, ZR, Glader, BE, McCarthy, MC, Mahoney, DH, Olson, TA, Feig, SA, Lorenzana, AN, Mentzer, WC, Buchanan, GR & Neufeld, EJ 2009, 'One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab', Pediatric Blood and Cancer, vol. 52, no. 2, pp. 259-262. https://doi.org/10.1002/pbc.21757

@article{25cbb5385d954a2885bf369ca8e86b24,

title = "One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab",

abstract = "Background. We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm3 within the first 12 weeks. These patients were followed for the next year. Methods. Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results. Eight of the 11 initial responders maintained a platelet count over 150,000/mm3 without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm3 without the need for further intervention. Conclusions. Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm 3 or higher in 11 of 36 patients (31%).",

keywords = "Clinical trial, Immune thrombocytopenia, Rituximab",

author = "Mueller, {Brigitta U.} and Bennett, {Carolyn M.} and Feldman, {Henry A.} and Bussel, {James B.} and Abshire, {Thomas C.} and Moore, {Theodore B.} and Hadi Sawaf and Loh, {Mignon L.} and Rogers, {Zora R.} and Glader, {Bertil E.} and McCarthy, {Maggie C.} and Mahoney, {Donald H.} and Olson, {Thomas A.} and Feig, {Stephen A.} and Lorenzana, {Adonis N.} and Mentzer, {William C.} and Buchanan, {George R.} and Neufeld, {Ellis J.}",

year = "2009",

month = feb,

doi = "10.1002/pbc.21757",

language = "English (US)",

volume = "52",

pages = "259--262",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab

AU - Mueller, Brigitta U.

AU - Bennett, Carolyn M.

AU - Feldman, Henry A.

AU - Bussel, James B.

AU - Abshire, Thomas C.

AU - Moore, Theodore B.

AU - Sawaf, Hadi

AU - Loh, Mignon L.

AU - Rogers, Zora R.

AU - Glader, Bertil E.

AU - McCarthy, Maggie C.

AU - Mahoney, Donald H.

AU - Olson, Thomas A.

AU - Feig, Stephen A.

AU - Lorenzana, Adonis N.

AU - Mentzer, William C.

AU - Buchanan, George R.

AU - Neufeld, Ellis J.

PY - 2009/2

Y1 - 2009/2

N2 - Background. We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm3 within the first 12 weeks. These patients were followed for the next year. Methods. Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results. Eight of the 11 initial responders maintained a platelet count over 150,000/mm3 without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm3 without the need for further intervention. Conclusions. Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm 3 or higher in 11 of 36 patients (31%).

AB - Background. We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm3 within the first 12 weeks. These patients were followed for the next year. Methods. Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results. Eight of the 11 initial responders maintained a platelet count over 150,000/mm3 without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm3 without the need for further intervention. Conclusions. Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm 3 or higher in 11 of 36 patients (31%).

KW - Clinical trial

KW - Immune thrombocytopenia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=59449095901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449095901&partnerID=8YFLogxK

U2 - 10.1002/pbc.21757

DO - 10.1002/pbc.21757

M3 - Article

C2 - 18937333

AN - SCOPUS:59449095901

SN - 1545-5009

VL - 52

SP - 259

EP - 262

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

ER -

One year follow-up of children and adolescents with chronic Immune Thrombocytopenic Purpura (ITP) treated with rituximab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this